---
title: "BMO Capital Reaffirms Their Buy Rating on Gilead Sciences (GILD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296223195.md"
description: "BMO Capital analyst Evan Seigerman reaffirmed a Buy rating on Gilead Sciences (GILD) with a $174 price target, noting the stock closed at $138.92. This follows other recent ratings, including a Buy from J.P. Morgan and a Hold from Barclays."
datetime: "2026-08-18T11:37:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296223195.md)
  - [en](https://longbridge.com/en/news/296223195.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296223195.md)
generator: "portal-rs"
---

# BMO Capital Reaffirms Their Buy Rating on Gilead Sciences (GILD)

In a report released yesterday, Evan Seigerman from BMO Capital reiterated a Buy rating on Gilead Sciences, with a price target of $174.00. The company’s shares closed yesterday at $138.92.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Seigerman is a 5-star analyst with an average return of 10.7% and a 59.19% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Pfizer.

In addition to BMO Capital, Gilead Sciences also received a Buy from J.P. Morgan’s Chris Schott in a report issued on August 6. However, on August 13, Barclays maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296835852.md)
- [Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296674916.md)
- [Is Gilead (GILD) Using AI Tissue Analytics To Quietly Redefine Its Oncology Edge?](https://longbridge.com/en/news/296706386.md)
- [WealthShield Partners LLC Buys New Holdings in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296699060.md)
- [Foster & Motley Inc. Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296455189.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**